NCT04526704View on ClinicalTrials.gov

Study to Evaluate Discontinuation and Re-Treatment in Participants With Tenosynovial Giant Cell Tumor (TGCT) Previously Treated With Pexidartinib

PHASE4CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

October 20, 2020

Primary Completion Date

July 7, 2023

Study Completion Date

July 7, 2023

Conditions
Tenosynovial Giant Cell Tumor
Interventions
DRUG

Pexidartinib

200 mg capsules administered orally twice daily on an empty stomach (at least 1 hour before or at least 2 hours after a meal or snack)

Trial Locations (16)

2050

Chris O'Brien Lifehouse, Camperdown

3000

Peter MacCallum Cancer Centre, East Melbourne

10065

Memorial Sloan Kettering Cancer Center, New York

20133

Fondazione IRCC Istituto Nazionale dei Tumori, Milan

33136

Sylvester Comprehensive Cancer Center, Miami

40136

Rizzoli-Istituto Ortopedico Rizzoli, Bologna

41013

Hospital Virgen del Rocio, Seville

63110

Washington University, St Louis

85258

Honor Health, Scottsdale

90033

USC Norris Comprehensive Cancer Center, Los Angeles

97239

Oregon Health & Science University, Portland

02215

Dana-Farber Cancer Institute, Boston

H-1062

Magyar Honvedseg Egeszsegugyi Kozpont, Budapest

2333 ZA

Leiden University Medical Center (LUMC), Leiden

08041

Hospital Sant Pau, Barcelona

Unknown

National Taiwan University Hospital, Taipei

Sponsors

Lead Sponsor

Daiichi Sankyo
All Listed Sponsors
lead

Daiichi Sankyo

INDUSTRY

NCT04526704 - Study to Evaluate Discontinuation and Re-Treatment in Participants With Tenosynovial Giant Cell Tumor (TGCT) Previously Treated With Pexidartinib | Biotech Hunter | Biotech Hunter